[go: up one dir, main page]

PL2624833T3 - Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów - Google Patents

Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów

Info

Publication number
PL2624833T3
PL2624833T3 PL11773326T PL11773326T PL2624833T3 PL 2624833 T3 PL2624833 T3 PL 2624833T3 PL 11773326 T PL11773326 T PL 11773326T PL 11773326 T PL11773326 T PL 11773326T PL 2624833 T3 PL2624833 T3 PL 2624833T3
Authority
PL
Poland
Prior art keywords
methylaminophenoxy
pyrdin
treating cancer
benzamide derivatives
benzamide
Prior art date
Application number
PL11773326T
Other languages
English (en)
Inventor
Takashi Nakagawa
Makoto Sakamoto
Kazuya Yamaguchi
Yuki Terauchi
Masamichi Shirakura
Yasuo Harada
Yutaka Kojima
Takumi Sumida
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of PL2624833T3 publication Critical patent/PL2624833T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11773326T 2010-10-04 2011-10-03 Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów PL2624833T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38939310P 2010-10-04 2010-10-04
EP20110773326 EP2624833B1 (en) 2010-10-04 2011-10-03 4-(methylaminophenoxy)pyrdin-3-yl-benzamide derivatives for treating cancer
PCT/JP2011/073165 WO2012046825A1 (en) 2010-10-04 2011-10-03 4- (methylaminophenoxy) pyrdin- 3 - yl - benzamide derivatives for treating cancer

Publications (1)

Publication Number Publication Date
PL2624833T3 true PL2624833T3 (pl) 2015-05-29

Family

ID=44872549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11773326T PL2624833T3 (pl) 2010-10-04 2011-10-03 Pochodne 4-(metyloaminofenoksy)pirydyn-3-ylo-benzamidu do leczenia nowotworów

Country Status (29)

Country Link
US (8) US8946437B2 (pl)
EP (1) EP2624833B1 (pl)
JP (1) JP5715690B2 (pl)
KR (1) KR101797797B1 (pl)
CN (1) CN103189061B (pl)
AR (1) AR083287A1 (pl)
AU (1) AU2011313236B2 (pl)
BR (1) BR112013007841B1 (pl)
CA (1) CA2813153C (pl)
CO (1) CO6660459A2 (pl)
DK (1) DK2624833T3 (pl)
EA (1) EA021627B1 (pl)
ES (1) ES2526574T3 (pl)
HR (1) HRP20141237T1 (pl)
IL (1) IL225520A (pl)
MX (1) MX2013003589A (pl)
MY (1) MY157563A (pl)
NZ (1) NZ609151A (pl)
PH (1) PH12013500605B1 (pl)
PL (1) PL2624833T3 (pl)
PT (1) PT2624833E (pl)
RS (1) RS53749B1 (pl)
SG (1) SG189146A1 (pl)
SI (1) SI2624833T1 (pl)
SM (1) SMT201500056B (pl)
TW (1) TWI526431B (pl)
UA (1) UA110037C2 (pl)
WO (1) WO2012046825A1 (pl)
ZA (1) ZA201302332B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2624833T1 (sl) * 2010-10-04 2015-03-31 Otsuka Pharmaceutical Co., Ltd. Derivati 4-(metilaminofenoksi)piridin-3-il-benzamida za zdravljenje raka
JP6066806B2 (ja) * 2012-04-03 2017-01-25 大塚製薬株式会社 医薬
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition
CN118005541B (zh) * 2023-12-13 2025-05-30 张家港格瑞特化学有限公司 一种双牛磺酸盐及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
JP2001089412A (ja) 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
EP1773797A2 (en) 2004-08-06 2007-04-18 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
SI1957073T1 (sl) 2005-12-05 2014-08-29 Otsuka Pharmaceutical Co., Ltd. A Corporation Organized Under The Laws Of Japan Medicinsko zdravilo
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
SI2624833T1 (sl) * 2010-10-04 2015-03-31 Otsuka Pharmaceutical Co., Ltd. Derivati 4-(metilaminofenoksi)piridin-3-il-benzamida za zdravljenje raka
SG11202108523UA (en) * 2019-03-25 2021-09-29 Otsuka Pharma Co Ltd Antitumor composition

Also Published As

Publication number Publication date
CO6660459A2 (es) 2013-04-30
TWI526431B (zh) 2016-03-21
US20200031773A1 (en) 2020-01-30
CA2813153A1 (en) 2012-04-12
IL225520A (en) 2016-05-31
AU2011313236B2 (en) 2016-05-19
US20240417376A1 (en) 2024-12-19
HRP20141237T1 (hr) 2015-02-13
NZ609151A (en) 2015-01-30
KR101797797B1 (ko) 2017-11-14
PH12013500605A1 (en) 2013-05-06
US20170298023A1 (en) 2017-10-19
JP2013538785A (ja) 2013-10-17
RS53749B1 (sr) 2015-06-30
US20150105432A1 (en) 2015-04-16
SI2624833T1 (sl) 2015-03-31
EA201390323A1 (ru) 2013-09-30
CN103189061A (zh) 2013-07-03
UA110037C2 (uk) 2015-11-10
WO2012046825A1 (en) 2012-04-12
ES2526574T3 (es) 2015-01-13
AR083287A1 (es) 2013-02-13
MX2013003589A (es) 2013-06-24
CA2813153C (en) 2019-01-15
TW201307289A (zh) 2013-02-16
US20130267565A1 (en) 2013-10-10
BR112013007841A2 (pt) 2016-06-07
DK2624833T3 (en) 2015-01-05
EA021627B1 (ru) 2015-07-30
CN103189061B (zh) 2015-09-02
US20180265471A1 (en) 2018-09-20
IL225520A0 (en) 2013-06-27
US8946437B2 (en) 2015-02-03
JP5715690B2 (ja) 2015-05-13
US20210017134A1 (en) 2021-01-21
EP2624833B1 (en) 2014-12-10
EP2624833A1 (en) 2013-08-14
KR20130121826A (ko) 2013-11-06
HK1187540A1 (en) 2014-04-11
US20230139808A1 (en) 2023-05-04
PH12013500605B1 (en) 2018-07-04
MY157563A (en) 2016-06-30
AU2011313236A1 (en) 2013-04-18
PT2624833E (pt) 2014-12-26
SMT201500056B (it) 2015-05-05
SG189146A1 (en) 2013-05-31
BR112013007841B1 (pt) 2020-03-03
ZA201302332B (en) 2014-07-30

Similar Documents

Publication Publication Date Title
IL223201A (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
PL2440545T3 (pl) Związki użyteczne do leczenia nowotworu
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
EP2542585B8 (en) Methods for treating colorectal cancer
SI2902030T1 (sl) Tienotriazolodiazepinske spojine za zdravljenje neoplazije
EP2542584B8 (en) Methods for treating pancreatic cancer
SI3412687T1 (sl) Postopek zdravljenja DLBCL
ZA201203449B (en) Sulfoxide derivatives for treating tumors
IL228644A0 (en) Cancer treatment methods
IL225623A0 (en) Psoriasis treatment methods
IL222958A0 (en) Cancer treatment
SI2742356T1 (sl) Prediktorji pri zdravljenju raka
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
IL225520A0 (en) History of 4-(methylaminophenoxy)pyridin-3-yl-benzamide for cancer treatment
PL2663318T3 (pl) Kompozycja farmaceutyczna do leczenia raka
WO2011137376A9 (en) Compounds for anti-fungal treatment
GB201019034D0 (en) Treatment for tumors
GB0914322D0 (en) Compounds for treating cancer
AU2012901918A0 (en) Methods for treating cancer
GB201010588D0 (en) Cancer treatment
ZA201405068B (en) Piperazinyl derivatives for the treatment of cancer